2-tert-Butoxycarbonylamino-3-(3-trifluoromethyl-phenyl)-propionic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-tert-Butoxycarbonylamino-3-(3-trifluoromethyl-phenyl)-propionic acid
• 英文别名: 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[3-(trifluoromethyl)phenyl]propanoic acid
• 化学式: C₁₅H₁₈F₃NO₄
• 分子量: 333.3
• InChiKey: SHMWDGGGZHFFRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE<br/>[FR] THIAZOLES SUBSTITUÉS PAR FLUOROISOQUINOLÉINE ET LEURS MÉTHODES D'APPLICATION
  申请人：AMGEN INC

  公开号：WO2010083246A1

  公开（公告）日：2010-07-22

  The invention relates to thiazole compounds of Formula (I) and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  该发明涉及式(I)的噻唑化合物及其组合物，用于治疗由蛋白激酶B（PKB）介导的疾病，其中变量具有此处提供的定义。该发明还涉及在治疗与异常细胞生长、癌症、炎症和代谢紊乱相关的疾病状态中使用这种噻唑化合物和其组合物的治疗用途。
• Phenylalanine derivative and proteinase inhibitor
  申请人：Okamoto, Shosuke

  公开号：EP0284632A1

  公开（公告）日：1988-10-05

  A phenylalanine derivative having the formula (I): wherein A represents (a) H2N-, (b) or B represents (a) (b) or wherein m is 0, 1, or 2 and n is 3, 4, or 5; X represents (a) hydroxy, (b) nitro, (c) amino, (d) phenoxy which may be substituted with (i) halogen or (ii) nitro, (e) C1-C4 alkyloxy which may be substituted with (i) phenyl or (ii) benzoyl, (f) benzoyl, (g) pyridyloxy which may be substituted with (i) halogen or (ii) nitro, or (h) C1-C4 alkyl which may be substituted with halogen; Y represents or -OR3 wherein R1 and R2 are independently (a) hydrogen, (b) phenyl which may be substituted with (i) benzoyl, (ii) C1-C4 alkylcarbonyl, (iii) C1-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl or hydroxycarbonyl, (iv) C2-Cs alkenyl which may be further substituted with hydroxycarbonyl or C1-C4 alkoxycarbonyl, (v) C1-C4 alkoxycarbonyl, or (vi) amidino, (c) pyridyl which may be substituted with halogen or carboxyl (d) imidazolyl, (e) pyrimidyl, (f) tetrazolyl, (g) thiazolyl which may be substituted with C,-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl, (h) C1-C6 alkyl which may be substituted with C1-C4 alkoxy, C1-C4 alkoxycarbonyl, phenyl, or benzoyl, (i) CS-C7 cycloalkyl which may be substituted with C1-C4 alkoxycarbonyl or (j) R' and R2 may form, with the nitrogen atom attached thereto, (i) pyperazyl which may be substituted on the nitrogen atom with C1-C4 alkyl which may be further substituted with phenyl, (ii) piperidino which may be substituted with carboxyl or C1-C4 alkoxycarbonyl, (iii) pyrrolidyl which may be substituted with C1-C4 alkoxycarbonyl, or (iv) morpholyl; and R3 represents (a) hydrogen, (b) C1-C6 alkyl which may be substituted with (i) C1-C4 alkoxy, (ii) phenyl, or (iii) pyridyl, or (c) pyridyl; or a pharmaceutically acceptable acid salt thereof. This phenylalanine derivative is effective as a proteinase.

  具有以下式（I）的苯丙氨酸衍生物：其中A代表（a）H2N-，（b）或B代表（a）（b）或其中m为0、1或2，n为3、4或5；X代表（a）羟基，（b）硝基，（c）氨基，（d）苯氧基，其可以被（i）卤素或（ii）硝基取代，（e）C1-C4烷氧基，其可以被（i）苯基或（ii）苯甲酰基取代，（f）苯甲酰基，（g）吡啶氧基，其可以被（i）卤素或（ii）硝基取代，或（h）C1-C4烷基，其可以被卤素取代；Y代表或-OR3，其中R1和R2独立地为（a）氢，（b）苯基，其可以被（i）苯甲酰基，（ii）C1-C4烷基羰基，（iii）C1-C4烷基，其可以进一步被C1-C4烷氧羰基或羟基羰基取代，（iv）C2-Cs烯烃基，其可以进一步被羟基羰基或C1-C4烷氧羰基取代，（v）C1-C4烷氧羰基，或（vi）酰胺基，（c）吡啶基，其可以被卤素或羧基取代（d）咪唑基，（e）嘧啶基，（f）四唑基，（g）噻唑基，其可以被C1-C4烷基取代，其可以进一步被C1-C4烷氧羰基取代，（h）C1-C6烷基，其可以被C1-C4烷氧基，C1-C4烷氧羰基，苯基或苯甲酰基取代，（i）C5-C7环烷基，其可以被C1-C4烷氧羰基取代或（j）R'和R2可以与其连接的氮原子形成（i）哌嗪基，其可以在氮原子上被C1-C4烷基取代，其可以进一步被苯基取代，（ii）哌啶基，其可以被羧基或C1-C4烷氧羰基取代，（iii）吡咯基，其可以被C1-C4烷氧羰基取代，或（iv）吗啉基；R3代表（a）氢，（b）C1-C6烷基，其可以被（i）C1-C4烷氧基，（ii）苯基或（iii）吡啶基取代，或（c）吡啶；或其药学上可接受的酸盐。该苯丙氨酸衍生物作为蛋白酶具有有效性。
• Heterocyclic modulators of PKB
  申请人：ZENG Qingping

  公开号：US20090275592A1

  公开（公告）日：2009-11-05

  The invention relates to heterocyclic compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种公式I的杂环化合物及其组合物，其中变量具有本文所提供的定义，其在治疗由蛋白激酶B（PKB）介导的疾病方面具有用途。本发明还涉及这种化合物和组合物在治疗与异常细胞生长、癌症、炎症和代谢紊乱相关的疾病状态方面的治疗用途。
• Thiadiazole modulators of PKB
  申请人：Zeng Qingping

  公开号：US20090298836A1

  公开（公告）日：2009-12-03

  The invention relates to thiazole compounds of Formula I and Formula II and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种化合物，其为公式I和公式II的噻唑化合物，以及其组合物，可用于治疗由蛋白激酶B（PKB）介导的疾病，其中变量具有本文中提供的定义。本发明还涉及在治疗异常细胞生长、癌症、炎症和代谢紊乱等疾病状态中使用这种噻唑化合物和其组合物的治疗用途。
• FLUOROISOQUINOLINE SUBSTITUTED THIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Zeng Qingping

  公开号：US20110263647A1

  公开（公告）日：2011-10-27

  The invention relates to thiazole compounds of Formula I and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种式I的噻唑化合物及其组合物，其在治疗由蛋白激酶B（PKB）介导的疾病方面具有用途，其中变量具有本文所提供的定义。本发明还涉及在治疗与异常细胞生长、癌症、炎症和代谢紊乱有关的疾病状态中使用此类噻唑化合物和其组合物的治疗用途。